NCT00002131已完成2 期
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 2
研究概览
简要总结
To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposi's sarcoma.
详细描述
Twenty-eight patients (14 per cohort) receive daily vesnarinone at one of two doses. At least seven patients at the lower dose must have completed 2 weeks of therapy before subsequent patients are entered at the higher dose. Patients who successfully complete 16 weeks of treatment may receive maintenance therapy for the duration of the study (approximately 12-18 months).
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria.
- •Acyclovir as acute treatment for herpes outbreaks.
- •Concurrent Treatment:
- •Limited electron-beam radiation therapy to non-marker lesions for treatment of Kaposi's sarcoma.
- •Patients must have:
- •Documented HIV infection.
- •Kaposi's sarcoma.
- •No current constitutional signs of HIV disease or AIDS-defining conditions other than Kaposi's sarcoma.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Active malignancy other than Kaposi's sarcoma, cutaneous basal cell carcinoma, or in situ carcinoma of the cervix.
- •Current significant cardiac disease or anomaly (including prolonged QTC on EKG).
- •Abnormal cardio-thoracic ratio on chest x-ray.
- •Concurrent Medication:
- •Antiretroviral agents, including ddI, ddC, AZT, and d4T.
- •Immunosuppressive agents.
- •Investigational HIV drugs/therapies including vaccines (except those on treatment IND for approved indications).
- •Other anti-Kaposi's sarcoma/HIV drugs.
- •Corticosteroids (other than topical).
- •Biologic response modifiers.
- •Megestrol acetate.
- •Agents known to cause neutropenia.
- •Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg sulfamethoxazole thrice weekly.
- •Cytotoxic chemotherapy.
- •Concurrent Treatment:
- •Radiation therapy including electron beam irradiation (other than limited electron-beam radiation to non-marker lesions for treatment of Kaposi's sarcoma).
- •Patients with the following prior conditions are excluded:
- •Prior history of significant cardiac disease or anomaly.
- •History of agranulocytosis or severe grade 3 drug-induced neutropenia or documented abnormalities in granulocyte function.
- •Prior Medication:
- •AZT within 14 days prior to study entry.
- •Acyclovir as prophylaxis for herpes within 48 hours prior to study entry.
- •Excluded within 30 days prior to study entry:
- •Interferon.
- •Biologic response modifiers.
- •Cytotoxic chemotherapy.
- •Prior Treatment:
- •Excluded within 30 days prior to study entry:
- •Blood or cellular blood product. Active illicit drug abuse (specifically cocaine, amyl nitrate, heroin, or other cardioactive agents).
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3HIV InfectionsNCT00002129Otsuka America Pharmaceutical36
已完成
2 期
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment FailureCytomegalovirus RetinitisHIV InfectionsNCT00000691National Institute of Allergy and Infectious Diseases (NIAID)156
已完成
2 期
SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to TreatmentSarcoma, KaposiHIV InfectionsNCT00005931SUGEN30
已完成
2 期
Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's SarcomaSarcoma, KaposiHIV InfectionsNCT00002259Lederle Laboratories
已完成
2 期
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)AIDS-Associated NephropathyHIV InfectionsNCT00000819National Institute of Allergy and Infectious Diseases (NIAID)54